44
Participants
Start Date
December 31, 2003
Primary Completion Date
August 31, 2004
Study Completion Date
September 30, 2004
MEDI-522
4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
Placebo
4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
NorthEast Clinical Research Centers, Inc, Allentown
Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta
North Florida Dermatology Associates, P.A., Jacksonville
Tenn. Clinical Research Center, INC, Nashville
Harmony Clinical Research, Johnson City
University of Cincinnati, Cincinnati
South Bend Clinic, South Bend
Midwest Cutaneous Research, Corp., Clinton Township
Central Dermatology, St Louis
Bressinck, Gibson, Parker, Dinehart, Sanster Dermatology, PA, Little Rock
Derm. Clinical Research Center of San Antonio, San Antonio
Dermatology Specialists, Vista
Associates In Research, Inc., Fresno
Solano Dermatology Associates, Vallejo
The Savin Center, P.C., New Haven
FutureCare Studies, INC, Springfield
Karen Harkaway, M.D., LLC, Riverside Park
Clincial Partners, LLC, Johnston
North Bay Dermatology Center, North Bay
Probity Medical Research, Inc., Waterloo
Lead Sponsor
MedImmune LLC
INDUSTRY